<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442402</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000734</org_study_id>
    <nct_id>NCT01442402</nct_id>
  </id_info>
  <brief_title>APOL1 Gene Variants in African American Kidney Transplant Recipients</brief_title>
  <official_title>Impact of APOL1 Gene Variants in African American Kidney Transplant Recipients: A Study of Clinical Outcomes and Molecular Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim 1:&#xD;
&#xD;
      Determine if there is an association between the APOL1 risk variants and allograft survival&#xD;
      and function in African Americans&#xD;
&#xD;
      Aim 2:&#xD;
&#xD;
      Determine if there is an association between the presence of APOL1 risk variants in an&#xD;
      African American kidney transplant recipient and the risk of recurrent disease&#xD;
&#xD;
      Aim 3:&#xD;
&#xD;
      Investigate mechanisms of APOL1 associated kidney disease by prospectively following African&#xD;
      American kidney transplant recipients throughout their clinical course.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding/resources&#xD;
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Allograft survival</measure>
    <time_frame>year 1, 3, 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allograft function as measured by serum creatinine</measure>
    <time_frame>creatinine levels at year-1, year-3 and year-5</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>Transplant;Failure,Kidney</condition>
  <condition>Kidney Disease</condition>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>2 APOL1 genotypes</arm_group_label>
    <description>African American transplant recipients with homozygous APOL1 gene variants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0 or 1 APOL1 genotypes</arm_group_label>
    <description>African American transplant recipients without homozygous APOL1 gene variants</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Aims 1 and 2:&#xD;
&#xD;
      Subjects will collect a saliva specimen in an Oragene®•DNA sample collection kit for&#xD;
      genotyping. We will also collected any discarded (no longer utilized for clinical purposes)&#xD;
      tissue from biopsies.&#xD;
&#xD;
      Aim 3:&#xD;
&#xD;
      Prior to transplant, subjects will collect saliva in an Oragene®•DNA sample collection kit&#xD;
      for genotyping and 10cc of blood will be drawn into a Na heparin collection tube for APOL1&#xD;
      protein analysis. When applicable, plasmapheresis effluent will be collected. We will also&#xD;
      collected any discarded (no longer utilized for clinical purposes)tissue from biopsies.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        African American Renal Transplant Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Aim 1:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  self-reported African American&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  kidney transplant within 12 years&#xD;
&#xD;
        Aim 2:&#xD;
&#xD;
        Inclusion Criteria for patients with recurrent disease:&#xD;
&#xD;
          -  self-reported African American&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  kidney transplant within 12 years&#xD;
&#xD;
          -  recurrent or de novo glomerular disease on allograft kidney biopsy&#xD;
&#xD;
        Inclusion Criteria for control group:&#xD;
&#xD;
          -  self-reported African American&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  kidney transplant within 12 years&#xD;
&#xD;
          -  end stage kidney disease due to glomerular nephritis, clinically diagnosed or by&#xD;
             native kidney biopsy&#xD;
&#xD;
        Exclusion Criteria for control group:&#xD;
&#xD;
          -  clinical evidence of recurrent disease (presence of proteinuria, hematuria, Creatinine&#xD;
             &gt;2)&#xD;
&#xD;
        Aim 3:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  self-reported African American&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  scheduled living kidney transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil K Chandraker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Anil K. Chandraker, MD</investigator_full_name>
    <investigator_title>Medical Director of Renal Transplantation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

